Collegium Pharmaceutical (COLL) came out with quarterly earnings of $2.04 per share, missing the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.99%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.88 per share when it actually produced earnings of $2.25, delivering a surprise of +19.68%.Over t ...

Core Insights - Korro Bio, Inc. is recognized as one of the best biotech stocks under $20, with significant potential for investment [1] Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing precision genetic medicines through RNA editing to address both rare and prevalent diseases [4] - The company utilizes its proprietary OPERA platform to advance RNA-editing therapies, which include both clinical and preclinical programs [4] Analyst Upgrades - H.C. Wainwright upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $20, emphasizing the independent value of KRRO-121 as a second risk-mitigated asset [2] - Chardan Capital also upgraded Korro Bio, Inc. from Neutral to Buy with a price target of $15, citing strong preclinical data for KRRO-121 and indicating that the company has "turned the page" [3]

Upgrades Summary - Barclays upgraded Zillow Group (ZG) to Equal Weight from Underweight with a price target of $72, increased from $66, citing that significant downside risks are already reflected in the stock price [2] - Rosenblatt upgraded Fortinet (FTNT) to Buy from Neutral with a price target of $100, up from $85, based on positive channel checks indicating a "meaningful inflection" in demand ahead of the Q4 report on February 5 [2] - Benchmark upgraded Littelfuse (LFUS) to Buy from Hold with a price target of $360, following a strong Q4 report and an optimistic outlook as demand improves across the business [2] - Morgan Stanley upgraded Cencora (COR) to Overweight from Equal Weight with a price target of $400, up from $361, highlighting the company's leadership in specialty markets, which will be enhanced by the acquisition of a majority stake in OneOncology [2] - Chardan upgraded Korro Bio (KRRO) to Buy from Neutral with a price target of $15 after the analyst day, indicating that the company has "turned the page" [2] - Piper Sandler also upgraded Korro Bio to Overweight from Neutral [2]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Serina Therapeutics, Inc. (SER) increased by 52% to $4.13 - Digital Currency X Technology Inc. (DCX) rose by 37% to $4.21 - Virtuix Holdings Inc. Class A Common Stock (VTIX) gained 31% to $14.00 - Venu Holding Corporation (VENU) saw a 25% increase to $6.45 - TRX Gold Corporation (TRX) was up 18% to $2.29 - Korro Bio, Inc. (KRRO) increased by 17% to $13.69 - Check-Cap Ltd. (MBAI) rose by 15% to $2.40 - Namib Minerals (NAMM) gained 14% to $7.35 - Austin Gold Corp. (AUST) increased by 11% to $2.84 - SuperX AI Technology Limited (SUPX) was up 9% to $19.12 [3] Premarket Losers - Inuvo, Inc. (INUV) decreased by 26% to $2.42 - Comstock Inc. (LODE) fell by 16% to $2.95 - Joby Aviation, Inc. (JOBY) dropped 14% to $11.40 - ENvue Medical, Inc. (FEED) declined by 12% to $2.02 - Whirlpool Corporation (WHR) was down 10% to $72.25 - USA Rare Earth, Inc. (USAR) decreased by 10% to $22.66 - ServiceNow, Inc. (NOW) fell by 9% to $117.41 - Pinnacle Food Group Limited (PFAI) dropped 9% to $2.15 - BiomX Inc. (PHGE) decreased by 8% to $5.91 - Vyome Holdings, Inc. (HIND) was down 8% to $2.32 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Premarket Gainers - Cidara Therapeutics, Inc. (CDTX) is up 91% at $203.18 - Binah Capital Group, Inc. (BCG) is up 45% at $2.07 - Invivyd, Inc. (IVVD) is up 42% at $2.52 - Omeros Corporation (OMER) is up 15% at $7.25 - The Oncology Institute, Inc. (TOI) is up 12% at $3.47 - AlphaVest Acquisition Corp (ATMV) is up 11% at $7.99 - ARB IOT Group Limited (ARBB) is up 7% at $7.31 - Hyperion DeFi, Inc. (HYPD) is up 6% at $5.27 - TruGolf Holdings, Inc. (TRUG) is up 6% at $2.02 - Boqii Holding Limited (BQ) is up 5% at $2.24 [3] Premarket Losers - TSS, Inc. (TSSI) is down 40% at $9.12 - StubHub Holdings, Inc. (STUB) is down 20% at $15.02 - ESS Tech, Inc. (GWH) is down 20% at $3.38 - Red Cat Holdings, Inc. (RCAT) is down 17% at $6.38 - WhiteFiber, Inc. (WYFI) is down 15% at $16.81 - New Era Energy & Digital, Inc. (NUAI) is down 13% at $3.66 - NET Power Inc. (NPWR) is down 11% at $2.62 - Korro Bio, Inc. (KRRO) is down 9% at $5.90 - Anavex Life Sciences Corp. (AVXL) is down 8% at $5.20 - Interactive Strength Inc. (TRNR) is down 5% at $2.47 [4]

Company Performance - JD.com reported a quarterly revenue growth of 14.9% year-over-year to $42.01 billion, surpassing the analyst consensus estimate of $41.33 billion [2] - JD posted an adjusted net income per ADS of 52 cents, exceeding the analyst consensus estimate of 34 cents [2] Stock Movements - Mersana Therapeutics Inc shares surged 205% to $27.06 after announcing its acquisition by Day One Biopharmaceuticals [8] - Nuvve Holding Corp shares increased 215% to $0.4916 following an aggregation agreement in Japan [8] - Ondas Holdings Inc shares rose 24% to $6.82 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [8] - Korro Bio Inc shares dropped 79% to $6.48 after announcing a wind-down of research and development activities [8] - Applied Therapeutics Inc shares fell 44% to $0.5070 following third-quarter results [8] - EPWK Holdings Ltd shares decreased 33% to $0.0434 after announcing a 40-for-1 share consolidation effective November 17 [8]

Company Performance - JD.com reported a quarterly revenue growth of 14.9% year-over-year to $42.01 billion, surpassing the analyst consensus estimate of $41.33 billion [2] - JD posted an adjusted net income per ADS of 52 cents, exceeding the analyst consensus estimate of 34 cents [2] Stock Movements - Mersana Therapeutics Inc shares surged 205% to $27.06 after announcing its acquisition by Day One Biopharmaceuticals [8] - Nuvve Holding Corp shares increased 215% to $0.4916 following an aggregation agreement in Japan [8] - Ondas Holdings Inc shares rose 24% to $6.82 after reporting better-than-expected third-quarter results and raising its FY25 sales guidance [8] - Korro Bio Inc shares dropped 79% to $6.48 after announcing a wind-down of research and development activities [8] - Applied Therapeutics Inc shares fell 44% to $0.5070 following third-quarter results [8] - EPWK Holdings Ltd shares decreased 33% to $0.0434 after announcing a 40-for-1 share consolidation effective November 17 [8]

Core Insights - The Russell 2000 index has rebounded significantly in Q3 2025, achieving its first all-time high since November 2021, driven by interest-rate-cut expectations and overall optimism in U.S. equities [1] - Nearly 60% of the Russell 2000 index components are trading above their 200-day moving average, indicating potential for further gains [2] - Notable top performers in the Russell 2000 index include Mercurity Fintech Holding, which surged by 538.44% over the past three months, and other companies showing substantial growth [4] Performance Highlights - The top performers in the Russell 2000 for Q3 include: - Mercurity Fintech Holding MFH (+538.44%) - Better Home & Finance Holdings BETR (+353%) - Kodiak Sciences KOD (+338.87%) - Korro Bio KRRO (+283.43%) - Celcuity CELC (+270.04%) - Bloom Energy BE (+253.55%) - American Battery Technology ABAT (+200%) [4] - Year-to-date best performers include: - Oncology Institute TOI (+1,029.45%) - Thredup TDUP (+579.86%) - Better Home & Finance Holdings BETR (+529.37%) - Oklo OKLO (+425.81%) - Palvella Therapeutics PVLA (+422.42%) [4][5]

Core Insights - Korro Bio, Inc. has appointed Dr. Loïc Vincent as Chief Scientific Officer, bringing over 20 years of drug development experience to the company [2][3] - The company is advancing multiple candidates in its pipeline, including KRRO-110, currently in Phase 1/2a clinical study for Alpha-1 Antitrypsin Deficiency [2] - Korro's RNA-editing platform aims to develop genetic medicines for both rare and prevalent diseases, enhancing precision and long-term tolerability [4] Company Overview - Korro Bio is a clinical-stage biopharmaceutical company focused on RNA editing to create genetic medicines [4] - The company utilizes an oligonucleotide-based approach to expand the reach of genetic therapies, leveraging established regulatory pathways [4] - Korro is headquartered in Cambridge, Massachusetts [4] Leadership Appointments - Dr. GaoZhong Zhu has joined as Senior Vice President of Chemistry, Manufacturing and Controls, with over 25 years of experience in pharmaceutical development [5] - Oliver Dolan has been promoted to Principal Accounting Officer, having served as Senior Vice President of Finance since January 2024 [5]

Table of Contents As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KORRO BIO, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Kingsley L. Taft, Esq. Marianne C. Sarrazin, Esq. Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000 Approximat ...